Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 14/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MARS1 | P56192 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629223 | 0.99 | RPA1 (0.58) | RPA1SMN1; SMN2NR4A2PPP1CANPC1 | |
| SCHEMBL1986774 | 0.85 | RPA1 (0.77) | RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL13902218 | 0.79 | RPA1 (0.55) | RPA1SMN1; SMN2PPP1CANPC1MAPT | |
| SCHEMBL14626195 | 0.77 | MKNK1 (0.43) | RPA1NR4A2NPC1MAPTRAB9A | |
| SCHEMBL13912443 | 0.77 | RPA1 (0.44) | RPA1NPC1MAPTRAB9A | |
| SCHEMBL12278777 | 0.77 | NR4A2 (0.49) | SMN1; SMN2NR4A2NPC1MAPTRAB9A | |
| SCHEMBL8369157 | 0.77 | RPA1 (0.65) | RPA1SMN1; SMN2PPP1CA | |
| SCHEMBL14591226 | 0.76 | RPA1 (0.51) | RPA1MARS1 | |
| SCHEMBL13902212 | 0.76 | RPA1 (0.51) | RPA1MARS1 | |
| SCHEMBL629916 | 0.76 | NPC1 (0.53) | RPA1NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534680-B1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACO INVESTMENTS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7501444-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501446-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-06-28 | — | — | US | disclosed |
| US-7166619-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY , INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20070010561-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-01-11 | — | — | US | disclosed |
| EP-1534279-A4 | PRENYLATION INHIBITORS CONTAINING DIMETHYL-CYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY INC (US) | 2006-11-08 | — | — | EP | disclosed |
| US-7112596-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1534680-A4 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY INC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060025454-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| US-6960603-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1534279-A2 | PRENYLATION INHIBITORS CONTAINING DIMETHYL-CYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534680-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050004122-A1 | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use | DEVELOPMENT PARTNERS, LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040116425-A1 | Prenylation inhibitors and methods of their synthesis and use | X-CHEM, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004016741-A2 | PRENYLATION INHIBITORS CONTAINING DIMETHYL-CYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004016592-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PPD DISCOVERY, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6649638-B1 | 5-Pyridin-3-yl-1H-pyrazole-3-carboxylic amide derivatives; cancer, restenosis, psoriasis, endometriosis, atherosclerosis, viral or yeast infection, and corneal neovascularization treatment | PPD DISCOVERY, INC. | 2003-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004122-A1 | Prenylation inhibitors containing dimethylcyclobutane and methods of their synthesis and use | RCE1, GGPS1, FNTA | RPA1 3143/4885SMN1; SMN2 3523/4885NR4A2 3479/4885 |
| US-20060025454-A1 | Prenylation inhibitors and methods of their synthesis and use | FNTA, RCE1, GGPS1 | RPA1 3242/4885SMN1; SMN2 3780/4885NR4A2 3749/4885 |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | FNTA, PTAR1, ZMPSTE24 | RPA1 3481/4885SMN1; SMN2 4110/4885NR4A2 2691/4885 |
| US-20040053970-A1 | Prenylation inhibitors and methods of their synthesis and use | FNTA, RCE1, GGPS1 | RPA1 3242/4885SMN1; SMN2 3780/4885NR4A2 3749/4885 |
| US-20070010561-A1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | FNTA, RCE1, GGPS1 | RPA1 3242/4885SMN1; SMN2 3780/4885NR4A2 3749/4885 |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | RCE1, GGPS1, FNTA | RPA1 3143/4885SMN1; SMN2 3523/4885NR4A2 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.